Zobrazeno 1 - 10
of 3 403
pro vyhledávání: ''
Autor:
Kullervo Hynynen, Vlad Agache, David E. Goertz, Raffi Karshafian, Margarita Todorova, Branson Chen, Omid Mortazavi
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e52307 (2012)
PLoS ONE
PLoS ONE
Ultrasound stimulated microbubbles (USMB) are being investigated for their potential to promote the uptake of anticancer agents into tumor tissue by exploiting their ability to enhance microvascular permeability. At sufficiently high ultrasound trans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f9f11662324da4f80905974fc88751
https://doi.org/10.32920/14668866
https://doi.org/10.32920/14668866
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In
Autor:
Xiaoling Xuei, J. Julie Kim, Minhua Wang, Oukseub Lee, Susan E. Clare, Seema A. Khan, Priyam Patel, Omid Hosseini, Matthew J. Schipma, Maarten C. Bosland, Irene Helenowski, Ali Shidfar
Publikováno v:
Cancer Letters. 520:255-266
Pharmacological approaches to breast cancer risk-reduction for BRCA1 mutation carriers would provide an alternative to mastectomy. BRCA1-deficiency dysregulates progesterone signaling, promoting tumorigenesis. Selective progesterone receptor (PR) mod
Autor:
Mohammad Reza Ahmadian, William L. Seibel, Yi Zheng, John P. Perentesis, Benjamin Mizukawa, Lisa M. Privette Vinnedge, Shailaja Hegde, Jose A. Cancelas, Oliver H.F. Krumbach, Yuan Lin, Mark Wunderlich, Nicolas Nassar, Anjelika Gasilina, Marcel Buchholzer, Mohammad Akbarzadeh
Publikováno v:
Leukemia. 36:637-647
Aberrant RHO guanine nucleotide exchange factor (RhoGEF) activation is chief mechanism driving abnormal activation of their GTPase targets in transformation and tumorigenesis. Consequently, a small-molecule inhibitor of RhoGEF can make an anti-cancer
Autor:
Shuichi Hironaka, Mitsuru Sasako, Nozomu Machida, Satoru Iwasa, Takaki Yoshikawa, Masanori Terashima, Ryo Sadachi, Narikazu Boku, Yasuhide Yamada
Publikováno v:
Japanese Journal of Clinical Oncology. 52:14-23
Background Although cisplatin and 5-chloro-2,4-dihydropyrimidine (dihydropyrimidine dehydrogenase inhibitor contained in S-1) are excreted into the urine, it remains unknown how creatinine clearance (CrCl) affects the safety and efficacy of cisplatin
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1418-1421 (2021)
Case Reports in Oncology
Case Reports in Oncology
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most serious adverse effects of chemotherapy. We experienced carboplatin (CBDCA)-induced akathisia-like CIPN, which was significantly attenuated by pregabalin administration, and report
Publikováno v:
Pediatric Hematology and Oncology. 39:215-224
Vascular endothelial growth factor-A (VEGF-A) is a master regulator of angiogenesis, with higher levels in infantile hemangioma (IH). The effects of propranolol on IH are not fully understood and may involve vasoconstriction, angiogenesis inhibition,
Autor:
Mianen Sun, Ly M. Nguyen, Elsa J. Brown, David S. Hong, Shumei Kato, Siqing Fu, Timothy A. Yap, Sarina Anne Piha-Paul, Vivek Subbiah, Daniel D. Karp, Jacob J. Adashek
Publikováno v:
Investigational New Drugs. 40:99-105
Background. Preclinical studies have shown that the combined inhibition of EGFR and NF-kB pathways to target the RalB/TBK1 pathway led to synergistic antitumor activity. Based on this rationale, we conducted a Phase I dose-escalation study combining
Autor:
Timothy F. Burns, Patrick J. Ward, D. Ross Camidge, Martina M. Koch, Carrianne Ludwig, Christine L. Hann, Maulik Patel, Afshin Dowlati, Daniel Morgensztern, Chris Chen, Halla Nimeiri, Philip Komarnitsky
Publikováno v:
Journal of Thoracic Oncology. 16:1582-1588
Introduction Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, a Notch pathway ligand highly expressed on SCLC cells. Rova-T was evaluated alone or in combination with platinum-based chemotherapy (cisplatin or carboplatin
Autor:
Shanu Modi
Publikováno v:
Future Oncology. 17:3415-3423
This is a summary of the article discussing the results of the DESTINY-Breast01 study originally published in the New England Journal of Medicine. The DESTINY-Breast01 study is a clinical study in participants with a type of breast cancer called HER2